Posts Tagged ‘Therapeutics’’

Lorus Therapeutics Announces Allowance of United States Patent for Cancer Drug LOR-2040 in the Treatment of Acute …

Lorus Therapeutics Announces Allowance of United States Patent for Cancer Drug LOR-2040 in the Treatment of Acute …
TORONTO, ONTARIO– – Lorus Therapeutics Inc. , a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer, today announced that the United States Patent and Trademark Office has allowed a new patent for the Company’s lead clinical stage cancer drug LOR-2040 in the treatment of Acute Myeloid Leukemia .

Read more on CCNMatthews via Yahoo! Finance

Eisai enters strategic drug discovery collaboration with FORMA Therapeutics

Eisai enters strategic drug discovery collaboration with FORMA Therapeutics
Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., and FORMA Therapeutics announced today that the two companies have signed a strategic drug discovery collaboration.

Read more on News-Medical-Net

Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress

Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress
WESTMINSTER, Colo.–(BUSINESS WIRE)–Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that results from the Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress — Milan, Italy from October 8-12, 2010 …

Read more on Business Wire

Allos Therapeutics Announces Topline Results From Phase 2b Study Of FOLOTYN In Patients With Advanced Non-Small Cell …

Allos Therapeutics Announces Topline Results From Phase 2b Study Of FOLOTYN In Patients With Advanced Non-Small Cell …
Allos Therapeutics, Inc. (NASDAQ:ALTH) announced topline results from the Company’s randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to …

Read more on Medical News Today

Novelos Therapeutics Announces Positive Phase 2 Results in NOV-002 Neoadjuvant Breast Cancer Trial at Sylvester …

Novelos Therapeutics Announces Positive Phase 2 Results in NOV-002 Neoadjuvant Breast Cancer Trial at Sylvester …
NEWTON, Mass.—-Novelos Therapeutics, Inc. , a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester …

Read more on Business Wire via Yahoo! Finance

$35 Million Investment Raised By Precision Therapeutics

$35 Million Investment Raised By Precision Therapeutics
Bain Capital Ventures, the venture and growth affiliate of Bain Capital, recently led a financing of $35 million in Precision Therapeutics. The funding will be used to provide additional support for expanding the distribution of the Company’s core product, ChemoFx®, and to expedite their efforts in the research, development and commercialization of novel proteomic and genomic markers for cancer …

Read more on PR Newswire via Yahoo! Finance

Nektar Therapeutics Announces Positive Initial Results from Phase 2 Study of NKTR-102 in Metastatic Breast Cancer

Nektar Therapeutics Announces Positive Initial Results from Phase 2 Study of NKTR-102 in Metastatic Breast Cancer
read more

Read more on SYS-CON Media

Regulus Therapeutics’ metabolic disease program data presented at Diabetes Keystone Symposium

Regulus Therapeutics’ metabolic disease program data presented at Diabetes Keystone Symposium
Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the “Diabetes” Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having …

Read more on News-Medical-Net

Prime Therapeutics to Present New Research at Academy of Managed Care Pharmacy Conference in April

Prime Therapeutics to Present New Research at Academy of Managed Care Pharmacy Conference in April
Prime Therapeutics LLC , a thought leader in pharmacy benefit management, will present five new studies at the Academy of Managed Care Pharmacy’s annual meeting, April 7-10, 2010 in San Diego.

Read more on PR Newswire via Yahoo! Finance

Research and Markets: Osteoporosis Drug Pipeline Report Reveals the Global Osteoporosis Therapeutics Market was Valued …

Research and Markets: Osteoporosis Drug Pipeline Report Reveals the Global Osteoporosis Therapeutics Market was Valued …
DUBLIN—-Research and Markets has announced the addition of GlobalData ‘s new report “Osteoporosis – Drug Pipeline Analysis and Market Forecasts to 2016″ to their offering.

Read more on Business Wire via Yahoo! Finance